The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia

Vaccine

Volumn 26, Issue 17, 2008, Pages 2142-2153

  Newall, Anthony T ^a,b,c   Scuffham, Paul A ^d   Kelly, Heath ^e   Harsley, Stuart ^f   MacIntyre, C Raina ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d GRIFFITH UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f CSL Biotherapies   (Australia)

Author keywords

Cost effectiveness; Influenza; Vaccination

Indexed keywords

INFLUENZA VACCINE; SIALIDASE INHIBITOR;

ADULT; ARTICLE; AUSTRALIA; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FLU LIKE SYNDROME; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MORTALITY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AUSTRALIA; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION;

EID: 41549131762     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.050     Document Type: Article

References (56)

1. Newall A.T., Wood J.G., and MacIntyre C.R. Influenza-related hospitalisation and death in Australians aged 50 years and older. Vaccine 26 (2008) 2135-2141
2. National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. (2003), Australian Government Department of Health and Ageing, Canberra
3. Australian Institute of Health and Welfare. 2004 adult vaccination survey: summary results. Canberra: AIHW & DoHA; 2005. Report No.: PHE 56.
4. Burckel E., Ashraf T., de Sousa Filho J.P., Forleo N.E., Guarino H., Yauti C., et al. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company. Pharmacoeconomics 16 5 Pt2 (1999) 563-576
5. Nichol K.L. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 161 5 (2001) 749-759
6. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 16 (2003) 1769-1775
7. Aballea S., Chancellor J., Martin M., Wutzler P., Carrat F., Gasparini R., et al. The cost-effectiveness of influenza vaccination for people aged 50-64 years: An international model. Value Health 10 2 (2007) 98-116
8. Maciosek M.V., Solberg L.I., Coffield A.B., Edwards N.M., and Goodman M.J. Influenza vaccination health impact and cost effectiveness among adults aged 50-64 and 65 and older. Am J Prev Med 31 1 (2006) 72-79
9. Turner D.A., Wailoo A.J., Cooper N.J., Sutton A.J., Abrams K.R., and Nicholson K.G. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 24 7 (2006) 1035-1043
10. Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., Strikas R.A., and Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55 10 (2006) 1-42
11. Commonwealth Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) Version 4.1 (2006), Commonwealth Department of Health and Ageing, Canberra
12. Britt H., Miller G.C., and Knox S. General practice activity in Australia 2004-2005 (2005), Australian Institute of Health and Welfare, Canberra
13. Family Medicine Research Centre. Bettering the evaluation and care of health (BEACH) report-influenza among patients aged 50-64 years in general practice 2000-2006 (2007), The University of Sydney at Westmead Hospital, Westmead
14. Neuzil K.M., Reed G.W., Mitchel Jr. E.F., and Griffin M.R. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 281 10 (1999) 901-907
15. Wong C.M., Chan K.P., Hedley A.J., and Peiris J.S. Influenza-associated mortality in Hong Kong. Clin Infect Dis 39 11 (2004) 1611-1617
16. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 292 11 (2004) 1333-1340
17. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 2 (2003) 179-186
18. Scuffham P.A. Estimating influenza-related hospital admissions in older people from GP consultation data. Vaccine 22 21/22 (2004) 2853-2862
19. Simonsen L., Fukuda K., Schonberger L.B., and Cox N.J. The impact of influenza epidemics on hospitalizations. J Infect Dis 181 3 (2000) 831-837
20. Li C.K., Choi B.C., and Wong T.W. Influenza-related deaths and hospitalizations in Hong Kong: a subtropical area. Public Health 120 6 (2006) 517-524
21. Dushoff J., Plotkin J.B., Viboud C., Earn D.J., and Simonsen L. Mortality due to influenza in the United States-an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 163 2 (2006) 181-187
22. Jefferson T.O., Rivetti D., Di Pietrantonj C., Rivetti A., and Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2 (2007) (CD001269)
23. Jimenez R., Larrauri A., Carrasco P., Esteban J., Gomez-Lopez L.I., and Gil A. Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50-64 years. Vaccine 21 25-26 (2003) 3550-3555
24. Kwong J.C., Sambell C., Johansen H., Stukel T.A., and Manuel D.G. The effect of universal influenza immunization on vaccination rates in Ontario. Health Rep 17 2 (2006) 31-40
25. Jefferson T., Demicheli V., Rivetti D., Jones M., Di P.C., and Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 367 9507 (2006) 303-313 [erratum appears in Lancet. 2006 Jun 24;367(9528):2060]
26. Aoki F.Y., Fleming D.M., Griffin A.D., Lacey L.A., and Edmundson S. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics 17 2 (2000) 187-195
27. Hawthorne G., and Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust NZ J Public Health 29 2 (2005) 136-142
28. Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Drummond M., and McGuire A. (Eds). Economic evaluation in health care (2001), Oxford University Press Inc., New York 94-112
29. Australian Bureau of Statistics. Australian demographic statistics (2005), Australian Bureau of Statistics, Canberra
30. AIHW GP Statistics and Classification Unit. SAND abstract No 9 from the BEACH program: Influenza and absenteeism.
31. Carrat F., Sahler C., Rogez S., Leruez-Ville M., Freymuth F., Le G.C., et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med 162 16 (2002) 1842-1848
32. AIHW GP Statistics and Classification Unit. SAND abstract No. 27 from the BEACH program: Influenza.
33. Akazawa M., Sindelar J.L., and Paltiel A.D. Economic costs of influenza-related work absenteeism. Value Health 6 2 (2003) 107-115
34. Keech M., Scott A.J., and Ryan P.J. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med 48 (1998) 85-90
35. Medicare Australia Statistical Unit. Additional data; 2007.
36. Family Medicine Research Centre. Bettering the evaluation and care of health (BEACH) report-influenza vaccination among patients aged 50-64 years in general practice 2000-2006 (2007), The University of Sydney at Westmead Hospital, Westmead
37. Commonwealth Department of Health and Ageing. National hospital cost data collection cost report round 9 (2004-2005) (2006), Commonwealth Department of Health and Ageing, Canberra
38. Commonwealth Department of Health and Ageing. National hospital cost data collection cost report round 7 (2002-2003) (2004), Commonwealth Department of Health and Ageing, Canberra
39. Australian Bureau of Statistics. Average Weekly Earnings, Australia; August 2005.
40. George B., Harris A., and Mitchell A. Cost effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia 1991-96 (1999), The Centre for Health Program Evaluation, Monash University, Melbourne
41. Glezen W.P., and Couch R.B. Estimating deaths due to influenza and respiratory syncytial virus. JAMA 289 19 (2003) 2500-2502 [comment]
42. Simonsen L., Blackwelder W.C., Reichert T.A., and Miller M.A. Estimating deaths due to influenza and respiratory syncytial virus. [comment]. JAMA 289 19 (2003) 2499-2500
43. Gay N.J., Andrews N.J., Trotter C.L., and Edmunds W.J. Estimating deaths due to influenza and respiratory syncytial virus. JAMA 289 19 (2003) 2499 [comment]
44. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di P.C., and Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366 9492 (2005) 1165-1174 [erratum appears in Lancet. 2006 Mar 25;367(9515):986]
45. Vu T., Farish S., Jenkins M., and Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 13/14 (2002) 1831-1836
46. Simonsen L., Reichert T.A., Viboud C., Blackwelder W.C., Taylor R.J., and Miller M.A. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 165 3 (2005) 265-272
47. Glezen W.P., and Simonsen L. Commentary: benefits of influenza vaccine in US elderly-new studies raise questions. Int J Epidemiol 35 2 (2006) 352-353
48. Jackson L.A., Jackson M.L., Nelson J.C., Neuzil K.M., and Weiss N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35 2 (2006) 337-344
49. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 333 7574 (2006) 912-915
50. Jefferson T., and Di P.C. Inactivated influenza vaccines in the elderly-are you sure?. Lancet 370 9594 (2007) 1199-1200
51. Simonsen L., Taylor R.J., Viboud C., Miller M.A., and Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet ID 7 10 (2007) 658-666
52. Turner D., Wailoo A., Nicholson K., Cooper N., Sutton A., and Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 7 35 (2003) 1-170
53. Taylor A., Wilson D., Dal Grande E., and Gill T. National influenza survey: (a population survey of vaccination uptake in Australia) October 2000 (2000), South Australian Department of Human Services, Adelaide
54. Glezen W.P., Decker M., and Perrotta D.M. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. American Review of Respiratory Disease 136 3 (1987) 550-555
55. Nguyen-Van-Tam J. Epidemiology of influenza. In: Nicholson K., Webster R., and Hay J. (Eds). Textbook of influenza (1998), Blackwell Science Ltd., Cornwall 181-206
56. MIMS database. http://mims.hcn.net.au; 2007.